子宮頸癌診斷市場規模 - 按診斷測試、年齡層和最終用戶 - 區域前景、競爭策略和細分市場預測（~2033 年）

Cervical Cancer Diagnostic Market Size- By Diagnostic Test, By Age Group, By End User- Regional Outlook, Competitive Strategies and Segment Forecast to 2033

出版日期: 2024年04月29日 | 出版商:

SPER Market Research Pvt. Ltd. | 英文 205 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計2033年，全球子宮頸癌診斷市場規模將成長至133.7億美元，複合年成長率為5.28%。

2020年的COVID-19對市場產生了重大影響，子宮頸癌診斷市場也因醫療服務中斷而面臨挑戰。由於注重 COVID-19 病例管理，子宮頸癌診斷數量減少，許多醫療機構推遲了非緊急手術和篩檢，影響了接受常規篩檢的女性數量。

本報告調查了全球子宮頸癌診斷市場，並提供了市場概況、市場影響因素和市場機會分析、市場規模趨勢和預測、各個細分市場/地區/主要國家的詳細分析、競爭格局，我們編制了主要的概況主要企業。

According to SPER market research, 'Cervical Cancer Diagnostic Market Size- By Diagnostic Test, Age Group, By End User- Regional Outlook, Competitive Strategies and Segment Forecast to 2033' state that the Global Cervical Cancer Diagnostic Market is predicted to reach 13.37 billion by 2033 with a CAGR of 5.28%.

Cervical cancer is a type of cancer that originates in the cervix. The thinner, lower end of the uterus is known as the cervix (womb). The uterus and vagina are connected via the cervix. Typically, it develops gradually over time. Dysplasia occurs in the cells of the cervix before cervical cancer develops. It begins to reveal aberrant cells in the cervical tissue. If the abnormal cells are not cleared or killed, they may eventually grow into malignant cells that proliferate and spread throughout the cervix and surrounding tissues.

The 2020 COVID-19 pandemic had a significant impact on the market. Cervical cancer diagnostics market faced challenges because to the COVID-19 pandemic-related disruptions in healthcare services. Cervical cancer diagnostics decreased as a result of the focus on COVID-19 case management. A significant number of healthcare facilities delayed non-urgent surgeries and screenings, which in turn affected the number of women receiving routine testing.

Scope of the Report:

Report Metric Details

Market size available for years 2020-2033

Base year considered 2023

Forecast period 2024-2033

Segments covered By Diagnostic Test, By Age Group, By End User

Regions covered North America, Asia-Pacific, Latin America, Middle East & Africa and Europe

Companies Covered Zilico, Siemens Healthineers AG, QIAGEN NV, Abbott Laboratories, Becton, Dickinson and Co, Quest Diagnostics Inc, F. Hoffmann-La Roche Ltd, Guided Therapeutics, Hologic Inc, Bio-Rad Laboratories.

Global Cervical Cancer Diagnostic Market Segmentation:

By Diagnostic Test: Based on the Diagnostic Test, Global Cervical Cancer Diagnostic Market is segmented as, Pap Smear Tests, HPV Test, Biopsy and ECC, Colposcopy Tests, Others.

By End User: Based on the End User, Global Cervical Cancer Diagnostic Market is segmented as; Hospitals, Speciality Clinics, Cancer and Radiation Therapy Centers, Diagnostic Centers, Others.

By Region: This research also includes data for North America, Asia-Pacific, Latin America, Middle East & Africa and Europe.

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPER's internal database
- 2.1.4. Premium insight from KOL's
2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges
4.2. COVID-19 Impacts of the Global Cervical Cancer Diagnostic Market.

5. Market variable and outlook

5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
5.3. PORTER's Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
5.4. Heat Map Analysis

6. Competitive Landscape

6.1. Global Cervical Cancer Diagnostic Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Cervical Cancer Diagnostic Market

7. Global Cervical Cancer Diagnostic Market, By Diagnostic Test (USD Million) 2020-2033

7.1. Global Cervical Cancer Diagnostic Market Size, Share and Forecast, By Diagnostic Test, 2020-2026
7.2. Global Cervical Cancer Diagnostic Market Size, Share and Forecast, By Diagnostic Test, 2027-2033
7.3. Pap Smear Tests
7.4. HPV Test
7.5. Biopsy and ECC
7.6. Colposcopy Tests
7.7. Others

8. Global Cervical Cancer Diagnostic Market, By Age Group (USD Million) 2020-2033

8.1. Global Cervical Cancer Diagnostic Market Size, Share and Forecast, By Age Group, 2020-2026
8.2. Global Cervical Cancer Diagnostic Market Size, Share and Forecast, By Age Group, 2027-2033
8.3. 20 to 40 years
8.4. above 40 years

9. Global Cervical Cancer Diagnostic Market, By End User (USD Million) 2020-2033

9.1. Global Cervical Cancer Diagnostic Market Size, Share and Forecast, By End User, 2020-2026
9.2. Global Cervical Cancer Diagnostic Market Size, Share and Forecast, By End User, 2027-2033
9.3. Hospitals
9.4. Specialty Clinics
9.5. Cancer and Radiation Therapy Centers
9.6. Diagnostic Centers
9.7. Others

10. Global Cervical Cancer Diagnostic Market Forecast, 2020-2033 (USD Million)

10.1. Global Cervical Cancer Diagnostic Market Size and Market Share

11. Global Cervical Cancer Diagnostic Market, By Region, 2020-2033 (USD Million)

11.1. Global Cervical Cancer Diagnostic Market Size and Market Share By Region (2020-2026)
11.2. Global Cervical Cancer Diagnostic Market Size and Market Share By Region (2027-2033)
11.3. Asia-Pacific
- 11.3.1. Australia
- 11.3.2. China
- 11.3.3. India
- 11.3.4. Japan
- 11.3.5. South Korea
- 11.3.6. Rest of Asia-Pacific
11.4. Europe
- 11.4.1. France
- 11.4.2. Germany
- 11.4.3. Italy
- 11.4.4. Spain
- 11.4.5. United Kingdom
- 11.4.6. Rest of Europe
11.5. Middle East and Africa
- 11.5.1. Kingdom of Saudi Arabia
- 11.5.2. United Arab Emirates
- 11.5.3. Qatar
- 11.5.4. South Africa
- 11.5.5. Egypt
- 11.5.6. Morocco
- 11.5.7. Nigeria
- 11.5.8. Rest of Middle-East and Africa
11.6. North America
- 11.6.1. Canada
- 11.6.2. Mexico
- 11.6.3. United States
11.7. Latin America
- 11.7.1. Argentina
- 11.7.2. Brazil
- 11.7.3. Rest of Latin America

12. Company Profile

12.1. Zilico
- 12.1.1. Company details
- 12.1.2. Financial outlook
- 12.1.3. Product summary
- 12.1.4. Recent developments
12.2. Siemens Healthineers AG
- 12.2.1. Company details
- 12.2.2. Financial outlook
- 12.2.3. Product summary
- 12.2.4. Recent developments
12.3. QIAGEN NV
- 12.3.1. Company details
- 12.3.2. Financial outlook
- 12.3.3. Product summary
- 12.3.4. Recent developments
12.4. Abbott Laboratories
- 12.4.1. Company details
- 12.4.2. Financial outlook
- 12.4.3. Product summary
- 12.4.4. Recent developments
12.5. Becton, Dickinson and Co.
- 12.5.1. Company details
- 12.5.2. Financial outlook
- 12.5.3. Product summary
- 12.5.4. Recent developments
12.6. Quest Diagnostics Inc.
- 12.6.1. Company details
- 12.6.2. Financial outlook
- 12.6.3. Product summary
- 12.6.4. Recent developments
12.7. F. Hoffmann-La Roche Ltd.
- 12.7.1. Company details
- 12.7.2. Financial outlook
- 12.7.3. Product summary
- 12.7.4. Recent developments
12.8. Guided Therapeutics
- 12.8.1. Company details
- 12.8.2. Financial outlook
- 12.8.3. Product summary
- 12.8.4. Recent developments
12.9. Hologic Inc.
- 12.9.1. Company details
- 12.9.2. Financial outlook
- 12.9.3. Product summary
- 12.9.4. Recent developments
12.10. Bio-Rad Laboratories Inc.
- 12.10.1. Company details
- 12.10.2. Financial outlook
- 12.10.3. Product summary
- 12.10.4. Recent developments
12.11. Others